163 related articles for article (PubMed ID: 9509677)
1. The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: a preliminary report.
Chiou TJ; Chim YS; Wei CH; Hsieh RK; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Nov; 60(5):229-35. PubMed ID: 9509677
[TBL] [Abstract][Full Text] [Related]
2. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
[TBL] [Abstract][Full Text] [Related]
5. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.
Dusenbery KE; McGuire WA; Holt PJ; Carson LF; Fowler JM; Twiggs LB; Potish RA
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(5):1079-84. PubMed ID: 8083076
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
8. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.
Sweeney PJ; Nicolae D; Ignacio L; Chen L; Roach M; Wara W; Marcus KC; Vijayakumar S
Br J Cancer; 1998 Jun; 77(11):1996-2002. PubMed ID: 9667681
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
Ludwig H; Sundal E; Pecherstorfer M; Leitgeb C; Bauernhofer T; Beinhauer A; Samonigg H; Kappeler AW; Fritz E
Cancer; 1995 Dec; 76(11):2319-29. PubMed ID: 8635038
[TBL] [Abstract][Full Text] [Related]
10. [Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response].
León Molinari P; Jiménez Monteagudo M; Barona Zamora P; Riol Diego M; Castro Paz L; Sierrasesúmaga Ariznavarreta L
An Esp Pediatr; 1998 Jul; 49(1):17-22. PubMed ID: 9718761
[TBL] [Abstract][Full Text] [Related]
11. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
12. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
Bösze P; Mayer A; Thurzó L; Kiss A; Rák K; Stumpf J
Orv Hetil; 1995 Nov; 136(47):2567-72. PubMed ID: 8532322
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
[TBL] [Abstract][Full Text] [Related]
14. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial.
Vijayakumar S; Roach M; Wara W; Chan SK; Ewing C; Rubin S; Sutton H; Halpern H; Awan A; Houghton A
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):721-9. PubMed ID: 8331011
[TBL] [Abstract][Full Text] [Related]
15. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
Henry DH; Beall GN; Benson CA; Carey J; Cone LA; Eron LJ; Fiala M; Fischl MA; Gabin SJ; Gottlieb MS
Ann Intern Med; 1992 Nov; 117(9):739-48. PubMed ID: 1416576
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.
Thomas G; Ali S; Hoebers FJ; Darcy KM; Rodgers WH; Patel M; Abulafia O; Lucci JA; Begg AC
Gynecol Oncol; 2008 Feb; 108(2):317-25. PubMed ID: 18037478
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.
Quirt I; Micucci S; Moran LA; Pater J; Browman G
Cancer Prev Control; 1997 Aug; 1(3):241-8. PubMed ID: 9765749
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.
Janicka L; Ksiazek A; Baranowicz I; Bednarek-Skublewska A; Mierzicki P; Ksiazek P
Int Urol Nephrol; 1998; 30(1):91-7. PubMed ID: 9569119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
